Bharat Book Bureau

This Industry Market Research report provides a detailed analysis of the Plant Nurseries in Australia industry, including key growth trends, statistics, forecasts, the competitive environment including market shares and the key issues facing the industry.

Industry Definition
The Plant Nurseries industry consists of businesses mainly engaged in propagating and growing ornamental plants, plants for transplanting into gardens (such as seedlings or young fruit trees) or bulbs. This includes the collection and planting of seeds or bulbs, the growing of plants and the sale to retail or wholesale establishments, landscapers, or to production horticulture (such as orchardists). This industry also includes units mainly engaged in growing turf. The Plant Nurseries industry does not include businesses involved in growing nursery stock for forests (included in industry A0303 - Services to Forestry in Australia) or those involved in growing flowers for seed collection (included in industry A0112 - Cut Flower and Flower Seed Growing in Australia).

Report Contents
The Key Statistics chapter provides the key indicators for the industry for at least the last three years. The statistics included are industry revenue, industry gross product, employment, establishments, exports, imports, domestic demand and total wages.

The Market Characteristics chapter covers the following: Market Size, Linkages, Demand Determinants, Domestic and International Markets, Basis of Competition and Life Cycle.

The Segmentation chapter covers the following: Products and Service Segmentation, Major Market Segments, Industry Concentration and Geographic Spread.

The Industry Conditions chapter covers the following: Barriers to Entry, Taxation, Industry Assistance, Regulation and Deregulation, Cost Structure, Capital and Labor Intensity, Technology and Systems, Industry Volatility and Globalization.

The Performance chapter provides an analysis of both the industry’s Current Performance and Historical Performance.

The Key Competitors chapter lists the major players in the industry as well as an analysis of each major player’s activities in the industry. Market share information is included where possible.

The Key Factors chapter covers the industry’s Key Sensitivities and Key Success Factors.

The Outlook chapter is a key analysis section of the report and outlines expectations for the key industry indicators over the next five year period, including forecasts.

For further information, please click on the following link: http://www.bharatbook.com/detail.asp?id=60971

Or

Contact us at:

Bharat Book Bureau
207, Hermes Atrium, Sector 11, PO Box.54, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com

Veterinary antibacterials—antiseptics that only act against bacteria—comprise some of the most important pharmaceutical products on the animal health market. Yet despite a difficult regulatory environment—driven by concerns over the development of antibacterial resistance in consumers of livestock products—new products are still being launched. This has resulted in significant changes in the animal health products market. This study offers a detailed examination of the shape of the animal health products market globally over the next several years specific to antibacterials, analyzing both the livestock and companion animal markets.

Table of Contents :  

1 Report Overview
1.1 Objectives of Report
1.2 Scope of Report
1.3 Methodology
1.4 Executive Summary

2 Animal Health Products Antibacterial Markets
2.1 Overview of Animal Health Products Market
2.1.1 World Products Market
2.1.2 U.S. Animal Health Products Market
2.1.3 European Animal Health Products Markets
2.1.4 Asian Animal Health Products Markets
2.2 Key Sector Highlights
2.3 Biologics Products Category
2.4 Companion Animal Health Products

3 Common Animal Diseases
3.1 Swine Fevers (African, Classical — Hog Cholera)
3.2 Yellow Fever
3.3 Anthrax
3.4 Crimean-Congo Hemorrhagic Fever
3.5 Foot and Mouth Disease (FMD)
3.6 Bovine Anaplasmosis
3.7 Bovine Babesiosis
3.8 Bovine Brucellosis
3.9 Bovine Genital Campylobacteriosis
3.10 Bovine Tuberculosis
3.11 Bovine Cysticercosis
3.12 Bovine Spongiform Encephalopathy
3.13 Dermatophilosis
3.14 Enzootic Bovine Leukosis
3.15 Hemorrhagic Septicemia
3.16 Infectious Bovine Rhinotracheitis / Infectious Pustular Vulvovaginitis
3.17 Theileriosis
3.18 Trichomonosis
3.19 Vesicular Stomatitis
3.20 Swine Vesicular Disease  Picornaviridae Enterovirus
3.21 Rinderpest
3.22 Peste Des Petits Ruminants
3.23 Contagious Bovine Pleuropneumonia
3.24 Lumpy Skin Disease
3.25 Rift Valley Fever
3.26 Bluetongue  Reoviridae Orbivirus
3.27 Ovine Epididymitis (Brucella Ovis)
3.28 Caprine and Ovine Brucellosis (Excluding B. Ovis)
3.29 Caprine Arthritis/Encephalitis
3.30 Contagious Agalactia
3.31 Contagious Caprine Pleuropneumonia
3.32 Enzootic Abortion of Ewes (Ovine Chlamydiosis)
3.33 Avian Chlamydiosis
3.34 Pullorum Disease
3.35 Myxomatosis
3.36 Tularemia
3.37 Contagious Equine Metritis
3.38 Dourine
3.39 Epizootic Lymphangitis
3.40 Porcine Brucellosis
3.41 Commercially-Significant Bacterial Infections in Farm Animals

4 Anti-bacterials Markets
4.1 Overview
4.2 Antibiotics Market Size
4.3 Global Sales of Animal Health Antibiotics by Region
4.3.1 U.S. Sales of Animal Health Antibiotics
4.3.2 European Sales of Animal Health Antibiotics
4.3.3 Japanese Sales of Animal Health Antibiotics
4.4 Animal Health Antibiotics Market Drivers
4.5 Growth Promotion in Livestock

5 Regulatory Overview of the Veterinary Health Market
5.1 Regulatory Environment
5.2 General Overview
5.3 Product Marketing Authority
5.4 Regulation of Animal Health Products in the European Union
5.5 Regulation of Animal Health Products in the U.S.
5.5.1 USDA
5.5.2 FDA
5.5.3 EPA
5.6 Regulation of Animal Health Products in Japan
5.6.1 Japanese Regulatory Environment
5.6.2 Withdrawal Periods
5.6.3 Japanese Filing Procedures for New Animal Drug Applications
5.6.4 Use of Outdated Animal Studies
5.6.5 Brand-Specific Listing for Antimicrobial, Antibiotic and Other Feed Additives
5.7 Proposed Regulation of Animal Antibiotics
5.8 Antibiotic Acquired Resistance and Animal Usage

6 Business Trends in the Industry
6.1 European Animal Health Industry
6.2 Trends Driving Demand
6.3 Antibiotic Usage
6.4 Mergers and Acquisitions
6.5 Bioterrorism and Food-brne PathogensWHO Guidelines
6.6 Animal Health Additive Growth Trends

7 Company Profiles
7.1 Abbott Laboratories
7.2 Agricultural Research Service
7.3 Alpharma, Inc.
7.4 BASF Agricultural Products and Nutrition
7.5 Bayer Animal Health
7.6 Boehringer Ingelheim Corp.
7.7 Elanco Animal Health
7.8 Fort Dodge Animal Health (Wyeth)
7.9 Heska Animal Health
7.10 Intervet International
7.11 IVAX Corporation
7.12 Merial Animal Health
7.13 Novartis Animal Health
7.14 Pfizer Animal Health
7.15 Roche Animal Nutrition and Health
7.16 Sanofi-Aventis
7.17 Schering-Plough Animal Health
7.18 Virbac S.A.
7.19 Wyeth (Fort Dodge Animal Health)

For further information, please click on the following link: http://www.bharatbook.com/detail.asp?id=83144

Or

Contact us at:

Bharat Book Bureau
207, Hermes Atrium, Sector 11, PO Box.54, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com

This report provides detailed data on imports into and exports from India of fruits and vegetables. The report starts with data on production of select fruits and vegetables. Fruits and vegetables covered by the report fall under chapters 7, 8 and 20 of HS Code. Taking a quick view at statistics of exports and imports of all fruits and vegetables under the above three chapters, items of importance for imports and exports are identified separately. In all, 29 items are selected as important in the imports basket and 47 selected as important in the exports. In addition to giving detailed country-wise statistics for each of the selected items, the report looks at patterns and trends in each of the selected items as well as of the category as a whole. The selected products are grouped into the following categories – fresh / chilled vegetables, frozen vegetables, prepared / preserved vegetables, dried vegetables, fresh / chilled fruits, nuts, dried fruits, dried leguminous vegetables (pulses), and products made from fruits / vegetables. The report has detailed country-wise import and export statistics for each selected product for the years 2004-05, 2005-06, 2006-07 and April-December 2007. 

Scope

The report covers the following areas:
· Historical data (3 years or more) on area, production and productivity of potato, onion, tomato, mushroom, banana, mango, citrus fruits, papaya, apple, grapes, pomegranate, coconut, areca nut, walnut, cashew nut

· Information about main cultivars / varieties grown in India along with peak season and states where grown

· Five-year data on production of all major fruits and vegetables grown in India

· Value of imports for 185 items for 2006-07 and April-December 2007

· Value of exports for 230 items for 2006-07 and April-December 2007

· Country-wise import statistics giving quantity and value for 29 items for the years 2004-05, 2005-06, 2006-07 and April-December 2007

· Country-wise export statistics giving quantity and value for 47 items for the years 2004-05, 2005-06, 2006-07 and April-December 2007

· Key factors influencing the exports / imports

· Analysis of trend of imports and exports in each of the following categories - fresh vegetables, frozen vegetables, prepared / preserved vegetables, dried
vegetables, fresh fruits, nuts, dried fruits, pulses, and products made from fruits / vegetables

Reasons to purchase
      200 pages packed with information
      165 tables & 4 charts
      Statistics from reliable official sources
      Statistics and trends based on them – no opinions
      Country-wise export data for each product for more than 3 past years
      Products categorized according to common understanding
      Imports and exports data for each category presented together to help understand the trend

For further information, please click on the following link: http://www.bharatbook.com/detail.asp?id=83499

Or

Contact us at:

Bharat Book Bureau
207, Hermes Atrium, Sector 11, PO Box.54, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com

This report is an essential source for data, analysis and strategic insight into Accuray Incorporated. The report provides key information relating to market share by sector and country, financial, SWOT and value chain analysis of the company. The report examines company’s business structure and operations, history and products, and provides an analysis of its key revenue lines. It inspects the company’s strategy, both in terms of its value chain positioning and strategic strengths and weaknesses.

Scope:-

 Revenues for the markets and sub-sectors Accuray Incorporated operates in by country and region.
 Detailed breakdowns of revenues and market share benchmarked against competitors.
 Profiles of the pipeline of products that the company is developing.
 Critical analysis of the company’s strengths, weaknesses opportunities and threats and positioning on the value chain.
 Provides summary analysis of key revenue lines and strategy.
 Details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.
 Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions.
 Latest mergers and acquisitions, partnerships or financings of the company, including debt, equity or venture finance.

Reasons to buy:-

 A single source to fulfill all of your business and competitor intelligence needs
 Research your competitors business structure, strategy and prospects.
 Counter your competitors strengths and target their weaknesses.
 Identify your competitors key revenue streams by market and geography.
 Identify and assess potential corporate and investment opportunities
 Support sales activities by understanding your customers businesses better.
 Identify potential competitor products before they reach market.
 Qualify prospective partners and suppliers.
For more information,kindly visit - http://www.bharatbook.com/detail.asp?id=82988

Bharatbook.com added a new report which provides information on the heavy truck industry in China and its past and current scenario.

China’s heavy truck industry had positive and negative impacts in its growth during the last decade. The variations are driven by oil prices and the macro-economy. The industry grew rapidly in the period of 2000-2004 whereas it had a negative growth in 2005. It recovered in 2006 and maintained the growth in 2007 which ranked first in terms of sales.

The sales of heavy truck jumped to 370,795 units in 2004 from 82,184 units in 2000, hitting the highest of industry cycle. In 2005, China’s heavy truck industry had a negative growth due to impact of macro-economic control and skyrocketing oil prices, making the industry fall down to the bottom of industry cycle. The sales in the year reached 236,600 trucks, decreased 36% year on year.
 
In 2006, the industry had a recovery growth, the sales stood at 307,300 trucks, increased 30% year on year. In 2007, the industry maintained the growth momentum in 2006; the sales reached 487,500 trucks, up 58.64% year on year. China National Heavy Duty Truck Group ranked the No.1 in terms of sales of 99,800 trucks, followed by FAW Group Corp. with sales of 96,200 trucks. Dongfeng Motor, Shaanxi Automobile Group and Fortan Motor ranked the third, fourth, fifth places respectively.
 
In the first half of 2008, the sales stood at 380,100 trucks, up 48.38% year on year. It is estimated that the sales will continue to grow in the second half of the year, but the growth rate will slow down.
 
Bharatbook.com included a new report “China Heavy Truck Industry Report, 2008” into its existing market research review. Based on the authoritative statistics of the National Bureau of Statistics and China Association of Automobile Manufacturers, this report makes a thorough study on the current situation, market size, profitability, competition and key companies of China’s heavy truck industry, and also makes a development forecast.

About Bharatbook.com:

Bharat Book Bureau facilitates companies to take the lead of their industry with best practice business strategies and intelligence, through a unique combination of published reports, databases, country reports, company profiles and customized research services. Bharat Book Bureau provides strategic information tools to the executives, business analysts, and knowledge managers that will help them to probe into and support critical, timely business decisions and strategies.

 For further information kindly visit: http://www.bharatbook.com/detail.asp?id=82184

Bharatbook.com added a new report which forecasts growth in advertising from digital media for the next ten years.
The incumbent telcos have largely failed to use triple or quadruple play effectively as a mechanism to propel themselves into the new market of digital media. From a marketing perspective this was not exactly a forgone conclusion, but perhaps from a vertically-integrated business position (especially with hindsight) it was.  Nevertheless the incumbents at least had a chance to show that they could jump the S-curve from the old telecoms market into a new digital media market. Telcos are great engineers but they are weak in marketing and media creativity. This is simply because the underlying vertically-integrated business models upon which their organisations are built do not stimulate innovation. Such organisations have to aim their products and services at mass market averages; they are not specialists in any of them. This leads to mediocre products. In the hyper-innovative and competitive Internet environment these mediocre offerings don’t stand a chance. Rather than utilising its unique mix of telco commodity (audio, video, data) around the emerging Internet business models, and using them to build new products, the telcos simply bundled the lot together, offering them at a marginal discount, and hoped for the best. With telco commodity prices dropping by the hour, there was no real incentive for users to take that discount as prices would drop anyway. Individual products could be obtained more cheaply by shopping around and building one’s own triple play model. There was also a reluctance to sign long-term triple play contracts – not a very attractive proposition in this volatile environment. What the telcos failed to do was create truly integrated products and to sell applications based on them, rather than simply bundling together the various building blocks. In the end, triple play was just another attempt to keep their vertically-integrated telco models running, rather than being a serious effort to build something better for their customers. Of all the triple play markets, Hong Kong might arguably have been the most successful. But there, also, the telco business culture has failed to match the one needed for the digital media. This realisation has assisted the incumbent telco PCCW to make the decision to try and interest others in their triple play business, in the hope that this will attract companies with a better view on what business models are required to operate within the digital economy. Private equity companies are eager to step into this particular breach and restructure businesses to make it more attractive for those companies to participate in the process. Bharatbook.com included a new report “Global Digital Media - Advertising and Marketing” which offers a wealth of information and analyses on the worldwide advertising and marketing sector in relation to Digital Media developments. It includes information and statistics on the worldwide advertising industry with a focus on online advertising developments. The report provides an overview of the key Internet Media players and their activities and a case study on the industry leader, Google. It includes an overview of marketing strategies such as permission and location based marketing. Information at a regional level is also provided for the Americas, Europe, Middle East, Africa and Asia Pacific. About Bharatbook.com:Bharat Book Bureau facilitates companies to take the lead of their industry with best practice business strategies and intelligence, through a unique combination of published reports, databases, country reports, company profiles and customized research services. Bharat Book Bureau provides strategic information tools to the executives, business analysts, and knowledge managers that will help them to probe into and support critical, timely business decisions and strategies.
For further information kindly visit: http://www.bharatbook.com/detail.asp?id=75126   

The global clinical trials business worth is estimated $50 Billion in 2008, with a growth rate of 10%.The market will show considerable growth in the future. An increased emphasis has been placed on cost-effectiveness of pharmaceutical R&D, as well as increased productivity to maintain the high output of recent years. Consequently, the pharmaceutical industry has witnessed rapid expansion of outsourced clinical services in both the West and in developing nations, most notably India and China. Importantly, pharmaceutical and biotechnological companies are increasingly delegating the responsibility of clinical trials to contract research organisations (CROs).The majority of the revenues generated by the clinical trials industry are due to large pharmaceutical companies outsourcing clinical research, the most crucial and expensive stage of drug development, to companies specialising in that work. The major challenge for the pharmaceutical companies in the next five years will be to maintain high growth rates. The branded pharmaceuticals market is under substantial pressure due to: Existing generic competition, Impending loss of major patents, and relatively thin pipeline.Because of the nature of the clinical trials industry it will, in turn, experience increasing pressures to deliver a cost-effective service. The demand among drugs companies for a more cost-efficient pipeline has therefore intensified in recent years. The strategy that pharmaceutical companies now seem to be applying to clinical trials mirrors the latest trends in the drug discovery section of development.Contract research organisations (CROs) are playing increasingly vital roles on behalf of manufacturers in the global drug development process, from conducting Phase I trials to post-marketing studies. It is often difficult for pharmaceutical and biotech companies to decide which CRO to offer a contract to. However, the market is undergoing rapid change over the coming years, with different companies approaching the challenges in different ways. The CRO market, however, continues to grow steadily at an average 10% yearly growth rate.Bharatbook.com included a new report “Global Clinical Trial Business Report & Analysis 2008-2018” which investigates the global market for such services, providing forecasts for revenues and expenditure there, as well as a comprehensive examination of principles driving and restraining the clinical trials market worldwide.  In Global Clinical Trial Business 2008-2018 provides the following essential information for understanding the clinical trial business:• The value of the clinical trial business market and its principal market segments from 2008 to 2018
• Which current or future therapies that will drive the market for clinical trial business from 2008 to 2018
• Market drivers and restraints, including a comprehensive SWOT analysis
• Comprehensive views of key opinion leaders on clinical trial business
• The companies involved in clinical trial business and their business strategy
• Forecasts for revenue in each of the phases of clinical trial business
• The present state of clinical trial business and future trends there
• What contract research opportunities exist for market entrants, both established companies and newcomers
• The main concerns for outsourcing clinical trials to CROs
• Ways to improve cost-effectiveness of clinical trial business
• Changes in clinical trial regulations
• Focus on drug safety issues.About Bharatbook.com:Bharat Book Bureau facilitates companies to take the lead of their industry with best practice business strategies and intelligence, through a unique combination of published reports, databases, country reports, company profiles and customized research services. Bharat Book Bureau provides strategic information tools to the executives, business analysts, and knowledge managers that will help them to probe into and support critical, timely business decisions and strategies.For further information kindly visit: http://www.bharatbook.com/detail.asp?id=81654 

For a number of years the European and Asian cellular phone industries have regarded themselves advanced from the US market, however, times are changing. With the launch of 3G services now starting to take place by network operators around the world, the US cellular industry is proving that it’s fast catching up.

The competitive situation in the US market and a slowness to license new spectrum has forced the biggest mobile operators to speed up the deployments of high-speed data services within their existing bands initially allocated for the PCS systems. With some of the key operators already launching 3G services in key markets, the US cellular industry is proving that, yet again, it’s not taking its future lightly.

Do you know what the 3G and wireless data strategy and plans of the key players are in the US market?
How will this affect your company’s future?
How can you make the most of the potential opportunities that will arise?

A new report published by it’s, “US 3G and wireless data services: market analysis and forecasts 2005-2010″, provides American, European and Asian companies with a thorough overall picture of what is happening in with US wireless data market. The report discusses network infrastructure deployment, and provides an in-depth focus on the country’s biggest mobile operators and their expected 3G strategies. Special attention is paid to the 3G standards types, revenue models, mobile data services, and thorough analysis of future developments in the US mobile telecoms market is provided along with total cellular subscriber and technology growth forecasts through to 2010.

With data expected to account for nearly 30 percent of total service revenues in the future, as an American company, are you making the most of the new trends of usage of data services on cell phones? Can your products further maximise their potential in the US cellular data marketplace?

For European and Asian companies, are you looking to get into the US cellular data market? The report provides key insight into this highly lucrative marketplace and offers an understanding of what services are currently being adopted.

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44654
_______________________________________________________________

Wouldn’t it be great if you could answer these 3 questions everytime?, Will a drug be successful?, Will a drug make any money?, Is it worth investing in a drugs’ further development?, In these days of thin pipelines and revenues consolidating into a few products there is high pressure your company’s product managers to be sure that their next product, if not a blockbuster, is at least a winner. However, you will be fully aware that through Pharmacoeconomics, we can go some way to predict the future success of your drug!

But questions still remain

Are Pharmacoeconomics any good?
Do Pharmacoeconomics work?
it’s’s brand new report, answers these questions for you. This new report examines the link between this new developmental tool, the financial success of drug and how decision makers are increasingly using Pharmacoeconomics to make their drug purchases - are you using Pharmacoeconomics successfully?

Currently there are 4 economic factors in a pharmacoeconomic evaluation :

Cost minimisation
Cost effectiveness analysis (CEA)
Cost benefit analysis (CBA)
Cost utility analysis (CUA)
it’s’s Pharmacoeconomics and Success in the Marketplace report, examines these steps and points out their usefulness in a drugs’ commercial viability and market positioning.

The report also tackles crucial issues such as :

Formulary decisions
The current effective structure of Pharmacoeconomics
Data problems in implementing and succeeding in Pharmacoeconomics
The influence of Pharmacoeconomics in the pharmaceutical R&D sector
Global Pharmacoeconomic practice from the major industry players

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44655
_______________________________________________________________

Driven by demographic trends, such as an increasing aged population, the global ophthalmic pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 13.0% to 2009.it’s’s latest report, ” The Global Ophthalmic Pharmaceutical Market 2004-2009 ” , explains just how this market will experience growth over the medium term future.

The world market is currently valued at $7.25bn and revenues are forecasts to rise to over $14bn in 2009. Do you know what the drivers and restraints of the market are? This report not only reveals these, but also details what stratergies can be used to maxmise profits from the drivers and restraints? Ensure your organisation is successful in this market by reserving your copy of it’s’s report today.

According to the findings of the new 170+page report, it’s reveals that Glaucoma therapies are set to dominate the market over the forecast period (2002-2009), accounting for almost 40% of market revenues by 2009. Indeed, 2004 saw the first blockbuster drug of the market, used to treat glaucoma.

Find out who are the major companies involved in the ophthalmic world market today and in the future. And what R&D opportunities exist for ‘new-comers’ to the ophthalmic pharmaceutical market.

In the process of providing a thorough evaluation of the market, the it’s Ophthalmics report focuses on the major therapeutic areas of the market:
Glaucoma
AMD
Ocular Allergies
Dry Eye Syndrome
Ocular Infections
Ocular Inflammation
Do you know what the market values of these major therapeutic areas of the ophthalmic world market are?

The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC ophthalmic drugs by disease and product type. The study also assess’s the challenges faced by ophthalmic companies, and what exciting market opportunites exist in this up- and-coming therapeutic area.

Why You Must Buy This Report?

This report features over 50 tables, 30 graphs and charts, news, insights, the latest developments and an in depth survey of the ophthalmics market with up-to-date analysis. This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company ‘the edge’ on your competitiors. You can not afford to be without this latest report from it’s.

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44656
_______________________________________________________________